Buprenorphine dosing choices in specific populations: review of expert opinion

References

• Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system improving public health and safety. JAMA. 2009;301(2):183–191.
   PubMed Web of Science ®Google Scholar
• Bell J. Medications in recovery: re-orientating drug dependence treatment Appendix C – opioid substitution treatment and its effectiveness: review of the evidence. National Treatment Agency for Substance Misuse. 2012 Jul 1–13.
   Google Scholar
• Summary of product characteristics: Subutex 0.4mg sublingual tablets. Slough: Indivior UK Limited; 2015.
   Google Scholar
• Martínez-Raga J, González Saiz F, Pascual C, et al. Suboxone® (buprenorphine/naloxone) as an agonist opioid treatment in Spain: a budgetary impact analysis. Eur Addict Res. 2010;16(1):31–42.
   PubMed Web of Science ®Google Scholar
• Donny EC, Brasser SM, Bigelow GE, et al. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction. 2005;100(10):1496–1509.
   PubMed Web of Science ®Google Scholar
• Donny EC, Walsh SL, Bigelow GE, et al. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology (Berl). 2002;161(2):202–212.
   PubMed Web of Science ®Google Scholar
• Dennis BB, Roshanov PS, Naji L, et al. Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria. Trials. 2015;16:475.
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949–958.
   PubMed Web of Science ®Google Scholar
• Waal H, Bussesund K, Clausen T, et al. SERAF RAPPORT 2/2015 En aldrende LAR-populasjon? Oslo: Senter for rus -og avhengighetsforskning seraf; 2015.
   Google Scholar
• INSERM. Chapitre 6: Consommation et mésusages chez les sujets sous médicaments de substitution aux opiacés. In: Medicaments Psychotropes : Consommations et pharmacodépendances. Rapport. Paris : Les éditions Inserm; 2012. p. 155–174.
   Google Scholar
• FedDerSerD. Progetto STAR (Strenghtening treatment access and retention for heroin addiction in Italia). Mariano Comense: Federazione Italiana degli Operatori dei Dipartimenti e dei Servizi delle Dipendenze; 2013.
   Google Scholar
• Launonen E, Alho H, Kotovirta E, et al. Diversion of opioid maintenance treatment medications and predictors for diversion among Finnish maintenance treatment patients. Int J Drug Policy. 2015;26(9):875–882.
   PubMed Web of Science ®Google Scholar
• Roncero C, Dominguez-Hernandez R, Diaz T, et al. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities. Adicciones. 2015;27(3):179–189.
   PubMed Web of Science ®Google Scholar
• D’Agnone O. Analysis of OST dosing from provider database. Personal communication. 2013.
   Google Scholar
• Lintzeris N, Clark N, Winstock A, et al. National clinical guidelines and procedures for the use of buprenorphine in the maintenance treatment of opioid dependence [Internet]. 2006 [cited 2016 Feb 26]. Available from: http://www.nationaldrugstrategy.gov.au/internet/drugstrategy/publishing.nsf/content/9011C92D2F6E1FC5CA2575B4001353B6/$File/bupren.pdf
   Google Scholar
• Farmer CM, Lindsay D, Williams J, et al. Practice guidance for buprenorphine for the treatment of opioid use disorders: results of an expert panel process. Subst Abus. 2015;36(2):209–216.
   PubMed Web of Science ®Google Scholar
• Doran C, Holmes J, Ladewig D, et al. Buprenorphine induction and stabilisation in the treatment of opiate dependence. Heroin Addict Relat Clin Probl. 2005;7:7–18.
   Google Scholar
• Nielsen S, Hillhouse M, Mooney L, et al. Comparing buprenorphine induction experience with heroin and prescription opioid users. J Subst Abuse Treat. 2012;43(3):285–290.
   PubMed Web of Science ®Google Scholar
• Gunderson EW, Levin FR, Rombone MM, et al. Improving temporal efficiency of outpatient buprenorphine induction. Am J Addict. 2011;20(5):397–404.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Hanna N, Laurenzi P, et al. Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres. Drug Alcohol Depend. 2008;94(1–3):125–132.
   PubMed Web of Science ®Google Scholar
• Hillhouse M, Canamar CP, Doraimani GT, et al. Participant characteristics and buprenorphine dose. Am J Drug Alcohol Abuse. 2011;37(5):453–459.
   PubMed Web of Science ®Google Scholar
• D’Amore A, Romano F, Biancolillo V, et al. Evaluation of buprenorphine dosage adequacy in opioid receptor agonist substitution therapy for heroin dependence: first use of the BUprenorphine-naloxone Dosage Adequacy eVAluation (BUDAVA) questionnaire. Clin Drug Investig. 2012;32(7):427–432.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Larance B, Degenhardt L, et al. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;5:CD011117. doi:10.1002/14651858.CD011117.pub2.
   PubMed Web of Science ®Google Scholar
• Fareed A, Vayalapalli S, Casarella J, et al. Effect of buprenorphine dose on treatment outcome. J Addict Dis. 2012;31(1):8–18.
   PubMed Web of Science ®Google Scholar
• Greenwald MK, Johanson C-E, Moody DE, et al. Effects of buprenorphine maintenance dose on μ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology. 2003;28(11):2000–2009.
   PubMed Web of Science ®Google Scholar
• Amass L, Pukeleviciene V, Subata E, et al. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals. Addiction. 2012;107(1):142–151.
   PubMed Web of Science ®Google Scholar
• Courty P. Use and abuse of high-dose buprenorphine (HDB) obtained without a prescription: a French survey. Heroin Addict Relat Clin Probl. 2009;11(1):23–30.
   Web of Science ®Google Scholar
• Roux P, Villes V, Blanche J, et al. Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management. Drug Alcohol Depend. 2008;97(1–2):105–113.
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Woody GE, Griffin ML, et al. Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study. Drug Alcohol Depend. 2010;107(2–3):253–256.
   PubMed Web of Science ®Google Scholar
• Comer SD, Sullivan MA, Vosburg SK, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010;105(4):709–718.
   PubMed Web of Science ®Google Scholar
• Fhima A, Henrion R, Lowenstein W, et al. Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex). Ann Méd Interne. 2001;152 Suppl:IS26–36.
   Google Scholar
• Khemiri A, Kharitonova E, Zah V, et al. Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims. Postgrad Med. 2014;126(5):113–120.
   PubMed Web of Science ®Google Scholar
• De Ducla M, Gagnon A, Mucchielli A, et al. Comparison of high dose buprenorphine treatments of opiate dependent outpatients in four healthcare networks. Ann Méd Interne. 2000;151 Suppl:B9–15.
   Google Scholar
• Summary of product characteristics: methadone hydrochloride DTF 1mg/1ml oral solution. Leeds: Rosemont Pharmaceuticals Limited; 2014.
   Google Scholar
• Ferri M, Minozzi S, Bo A, et al. Slow-release oral morphine as maintenance therapy for opioid dependence. Cochrane Database Syst Rev. 2013;6:CD009879.
   Google Scholar
• Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750–2755.
   PubMed Web of Science ®Google Scholar